CORC

在结果中检索

CORC

浏览/检索结果: 共27条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis 期刊论文
CLINICAL RHEUMATOLOGY, 2019, 卷号: 38, 期号: 6
作者:  Dong, Yidian;  Li, Ping;  Xu, Tingshuang;  Bi, Liqi
收藏  |  浏览/下载：12/0  |  提交时间：2019/12/05
A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects 期刊论文
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 卷号: 57, 期号: 3
作者:  Li, Cuiyun;  Zhang, Hong;  Zhu, Xiaoxue;  Wei, Haijing;  Chen, Hong
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05
Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system 期刊论文
DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 卷号: 13
作者:  An, Qing;  Zheng, Yingxin;  Zhao, Yirong;  Liu, Tao;  Guo, Huaizu
收藏  |  浏览/下载：15/0  |  提交时间：2019/12/05
HS016, A PROPOSED ADALIMUMAB BIOSIMILAR, SHOWED EQUIVALENT PHARMACOKINETICS AND SIMILAR SAFETY, IMMUNOGENICITY AND TOLERABILITY TO CHINA-LICENSED ADALIMUMAB IN HEALTHY MALE SUBJECTS, ACCORDING TO A 2.3-MONTHS PHASE I STUDY 会议论文
作者:  Cao, Guoying;  Yu, Jicheng;  Wang, Jingjing;  Yang, Xiaoli;  Xue, Yu
收藏  |  浏览/下载：17/0  |  提交时间：2019/12/05
A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects 期刊论文
BIODRUGS, 2019, 卷号: 33, 期号: 1
作者:  Zhang, Tan;  Chen, Guihong;  Liu, Chang;  Zu, Li'an;  Wang, Qi
收藏  |  浏览/下载：23/0  |  提交时间：2019/12/05
A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects 期刊论文
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2019, 卷号: 33, 页码: 93-100
作者:  Zhang Tan[1];  Chen Guihong[2];  Liu Chang[3];  Zu Li'an[4];  Wang Qi[5]
收藏  |  浏览/下载：38/0  |  提交时间：2019/04/22
EFFICACY, PHARMACOKINETICS, SAFETY AND IMMUNOGENICITY OF THE BIOSIMILAR HS016 IN COMPARISON WITH ADALIMUMAB IN CHINESE PATIENTS WITH ANKYLOSING SPONDYLITIS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 3 TRIAL 会议论文
ANNALS OF THE RHEUMATIC DISEASES, 2019-06-01
作者:  Su, Jinmei;  Li Mengtao;  Zeng, Xiaofeng
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03
EFFICACY, PHARMACOKINETICS, SAFETY AND IMMUNOGENICITY OF THE BIOSIMILAR HS016 IN COMPARISON WITH ADALIMUMAB IN CHINESE PATIENTS WITH ANKYLOSING SPONDYLITIS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 3 TRIAL 期刊论文
2019, 卷号: 78, 页码: 894-894
作者:  Su, Jinmei;  Li Mengtao;  Zeng, Xiaofeng
收藏  |  浏览/下载：9/0  |  提交时间：2020/01/03
BIOSIMILAR BAT1406 VERSUS ADALIMUMAB THERAPY ON ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLINDED, MULTICENTER, CONTROLLED PHASE 3 TRIAL 会议论文
Annual European Congress of Rheumatology (EULAR), JUN 12-15, 2019
作者:  Tu, Liudan;  Wei, Qiujing;  Xie, Ya;  Shi, Guixiu;  Liu, Huaxiang
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/31
Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study 期刊论文
ARTHRITIS & RHEUMATOLOGY, 2018, 卷号: 70
作者:  Wu, Lijun;  Xu Huji;  Li Zhijun;  Jian, Wu;  Qian, Xing
收藏  |  浏览/下载：26/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace